BANGALORE (Thomson Financial) - India's Biocon Ltd. and Nasdaq-listed Abraxis BioScience Inc. said they have launched breast cancer drug treatment Abraxane in India.
Breast cancer is the second most common cause of death among women diagnosed with cancer in India, the companies said in a joint stock exchange release.
The biotech company said the drug will be sold as a single-use 100 mg vial.
Abraxis Chairman Patrick Soon-Shiong said: 'In addition to India, our marketing agreement with Biocon covers more than 10 countries, and we are working closely with national authorities throughout the region to receive regulatory approvals and commence marketing activities as soon as possible.'
In August 2007, Biocon and Abraxis entered into a licensing deal for Abraxane in India, Pakistan, Bangladesh, Sri Lanka, the United Arab Emirates, Saudi Arabia, Kuwait and certain other South Asian and Persian Gulf countries.
The drug was approved by the Drug Controller General of India in October last year. TFN.newsdesk@thomson.com jjo/ran/slj COPYRIGHT Copyright Thomson Financial News Limited 2008. All rights reserved. The copying, republication or redistribution of Thomson Financial News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Financial News.
© 2008 AFX News
